These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25069592)

  • 1. Taste-masked orodispersible tablets of cyclosporine self-nanoemulsion lyophilized with dry silica.
    Zidan AS; Aljaeid BM; Mokhtar M; Shehata TM
    Pharm Dev Technol; 2015; 20(6):652-61. PubMed ID: 25069592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orodispersible tablets containing taste-masked solid lipid pellets with metformin hydrochloride: Influence of process parameters on tablet properties.
    Petrovick GF; Kleinebudde P; Breitkreutz J
    Eur J Pharm Biopharm; 2018 Jan; 122():137-145. PubMed ID: 29106946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and optimization of drug-loaded mesoporous silica nanoparticle-based tablets to improve the dissolution rate of the poorly water-soluble drug silymarin.
    Ibrahim AH; Smått JH; Govardhanam NP; Ibrahim HM; Ismael HR; Afouna MI; Samy AM; Rosenholm JM
    Eur J Pharm Sci; 2020 Jan; 142():105103. PubMed ID: 31648050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microwave-Assisted Development of Orally Disintegrating Tablets by Direct Compression.
    Kande KV; Kotak DJ; Degani MS; Kirsanov D; Legin A; Devarajan PV
    AAPS PharmSciTech; 2017 Aug; 18(6):2055-2066. PubMed ID: 27995465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation studies for mirtazapine orally disintegrating tablets.
    Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
    Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upgrading of dissolution and anti-hypertensive effect of Carvedilol via two combined approaches: self-emulsification and liquisolid techniques.
    Ibrahim TM; Abdallah MH; El-Megrab NA; El-Nahas HM
    Drug Dev Ind Pharm; 2018 Jun; 44(6):873-885. PubMed ID: 29254384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and evaluation of Cetirizine dihydrochloride orodispersible tablet.
    Subramanian S; Sankar V; Manakadan AA; Ismail S; Andhuvan G
    Pak J Pharm Sci; 2010 Apr; 23(2):232-5. PubMed ID: 20363705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride.
    Cantor SL; Khan MA; Gupta A
    Drug Dev Ind Pharm; 2015; 41(7):1156-64. PubMed ID: 25000481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation.
    Rahman Z; Siddiqui A; Khan MA
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1300-9. PubMed ID: 23800704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tadalafil-Loaded Limonene-Based Orodispersible Tablets: Formulation, in vitro Characterization and in vivo Appraisal of Gastroprotective Activity.
    Mehanna MM; Mneimneh AT; Domiati S; Allam AN
    Int J Nanomedicine; 2020; 15():10099-10112. PubMed ID: 33363369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of face centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets.
    Pabari RM; Ramtoola Z
    Int J Pharm; 2012 Jul; 430(1-2):18-25. PubMed ID: 22465631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
    Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
    Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of different approaches for preparation of chlorzoxazone orodispersible tablets.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Dev Ind Pharm; 2017 May; 43(5):742-750. PubMed ID: 27534668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and evaluation of taste-masked levocetirizine dihydrochloride orally disintegrating tablets.
    Devireddy SR; Gonugunta CS; Veerareddy PR
    PDA J Pharm Sci Technol; 2009; 63(6):521-6. PubMed ID: 20169858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation, preparation, and evaluation of novel orally disintegrating tablets containing taste-masked naproxen sodium granules and naratriptan hydrochloride.
    Stange U; Führling C; Gieseler H
    J Pharm Sci; 2014 Apr; 103(4):1233-45. PubMed ID: 24532095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, development and in-vitro evaluation of diclofenac taste-masked orodispersible tablet formulations.
    Guhmann M; Preis M; Gerber F; Pöllinger N; Breitkreutz J; Weitschies W
    Drug Dev Ind Pharm; 2015 Apr; 41(4):540-51. PubMed ID: 24495274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate.
    Liu Y; Li P; Qian R; Sun T; Fang F; Wang Z; Ke X; Xu B
    Drug Dev Ind Pharm; 2018 Aug; 44(8):1317-1327. PubMed ID: 29521132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro and in-vivo evaluation of taste-masked cetirizine hydrochloride formulated in oral lyophilisates.
    Preis M; Grother L; Axe P; Breitkreutz J
    Int J Pharm; 2015 Aug; 491(1-2):8-16. PubMed ID: 26051543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and evaluation of self-emulsifying orlistat tablet to enhance drug release and in vivo performance: factorial design approach.
    Gade MM; Hurkadale PJ
    Drug Deliv Transl Res; 2016 Jun; 6(3):276-88. PubMed ID: 27037924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression.
    Tafere C; Yilma Z; Abrha S; Yehualaw A
    PLoS One; 2021; 16(3):e0246648. PubMed ID: 33725014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.